Quote this publication Share Print

ACARIZAX (standardised allergen extract from the house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae)

ALLERGY MEDICINE - New medicinal product
Opinions on drugs - Posted on Jun 15 2017

Reason for request

Inclusion

No clinical benefit demonstrated in the treatment of allergic rhinitis and asthma

 

  • ACARIZAX, administered orally, has a Marketing Authorisation in adults with persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication and/or house dust mite allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe house dust mite allergic rhinitis.
  • Treatment is based on a diagnosis including a clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE).
  • No clinical benefit has been demonstrated compared with usual treatment of these patients. This is a second-line treatment for:

 -    persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication

 -    non-severe forms of house dust mite allergic asthma in adults, with an FEV1 ≥ 70% of predicted value, not well controlled despite moderate to significant doses of inhaled corticosteroids, and associated with mild to severe house dust mite allergic rhinitis.

 

 


Clinical Benefit

Low

-


Clinical Added Value

no clinical added value

-


Therapeutic use

-

Contact Us

Évaluation des médicaments